BNP Paribas Financial Markets’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2
Closed -$10 5874
2025
Q4
$10 Hold
2
﹤0.01% 5690
2025
Q3
$21 Sell
2
-101
-98% -$939 ﹤0.01% 5499
2025
Q2
$866 Hold
103
﹤0.01% 5161
2025
Q1
$957 Hold
103
﹤0.01% 5078
2024
Q4
$2.32K Hold
103
﹤0.01% 5004
2024
Q3
$3.86K Hold
103
﹤0.01% 3853
2024
Q2
$3.86K Hold
103
﹤0.01% 3783
2024
Q1
$3.46K Hold
103
﹤0.01% 3767
2023
Q4
$4.11K Hold
103
﹤0.01% 3765
2023
Q3
$3.27K Hold
103
﹤0.01% 3690
2023
Q2
$3.43K Hold
103
﹤0.01% 3694
2023
Q1
$4.57K Buy
103
+101
+5,050% +$8.1K ﹤0.01% 3590
2022
Q4
$151 Hold
2
﹤0.01% 3933
2022
Q3
$193 Hold
2
﹤0.01% 4612
2022
Q2
$337 Hold
2
﹤0.01% 3967
2022
Q1
$371 Hold
2
﹤0.01% 4046
2021
Q4
$536 Sell
2
-5
-71% -$1.31K ﹤0.01% 4108
2021
Q3
$2.06K Sell
7
-59
-89% -$17.2K ﹤0.01% 3799
2021
Q2
$16.3K Sell
66
-64
-49% -$16.5K ﹤0.01% 3589
2021
Q1
$37.2K Sell
130
-105
-45% -$41.9K ﹤0.01% 3675
2020
Q4
$65.6K Sell
235
-1,639
-87% -$607K ﹤0.01% 3428
2020
Q3
$764K Buy
1,874
+1,842
+5,756% +$946K ﹤0.01% 1957
2020
Q2
$18.8K Buy
+32
New +$14.6K ﹤0.01% 3425

Other funds holding CODX

BNP Paribas Financial Markets's CODX Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of Co-Diagnostics (CODX) in Q1 2026, closing a stake of 2 shares — an estimated $10 sold.

BNP Paribas Financial Markets first reported a position in CODX in Q2 2020 and held it in 23 quarters. The position peaked at $764K in Q3 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • BNP Paribas Financial Markets reported no remaining Co-Diagnostics position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 2 Co-Diagnostics shares in Q1 2026, an estimated $10.
  • BNP Paribas Financial Markets first reported a position in Co-Diagnostics in Q2 2020 and held it in 23 quarters.
  • BNP Paribas Financial Markets's Co-Diagnostics position peaked at $764K in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.